606 related articles for article (PubMed ID: 23703868)
21. High-density lipoprotein administration attenuates liver proinflammatory response, restores liver endothelial nitric oxide synthase activity, and lowers portal pressure in cirrhotic rats.
Thabut D; Tazi KA; Bonnefont-Rousselot D; Aller M; Farges O; Guimont MC; Tellier Z; Guichard C; Ogier-Denis E; Poynard T; Moreau R; Lebrec D
Hepatology; 2007 Dec; 46(6):1893-906. PubMed ID: 17918268
[TBL] [Abstract][Full Text] [Related]
22. HSC-specific inhibition of Rho-kinase reduces portal pressure in cirrhotic rats without major systemic effects.
Klein S; Van Beuge MM; Granzow M; Beljaars L; Schierwagen R; Kilic S; Heidari I; Huss S; Sauerbruch T; Poelstra K; Trebicka J
J Hepatol; 2012 Dec; 57(6):1220-7. PubMed ID: 22878469
[TBL] [Abstract][Full Text] [Related]
23. Soluble guanylyl cyclase stimulation and phosphodiesterase-5 inhibition improve portal hypertension and reduce liver fibrosis in bile duct-ligated rats.
Brusilovskaya K; Königshofer P; Lampach D; Szodl A; Supper P; Bauer D; Beer A; Stift J; Timelthaler G; Oberhuber G; Podesser BK; Seif M; Zinober K; Rohr-Udilova N; Trauner M; Reiberger T; Schwabl P
United European Gastroenterol J; 2020 Dec; 8(10):1174-1185. PubMed ID: 32878579
[TBL] [Abstract][Full Text] [Related]
24. Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats.
Laleman W; Van Landeghem L; Van der Elst I; Zeegers M; Fevery J; Nevens F
Gastroenterology; 2007 Feb; 132(2):709-19. PubMed ID: 17258737
[TBL] [Abstract][Full Text] [Related]
25. PPARα activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats.
Rodríguez-Vilarrupla A; Laviña B; García-Calderó H; Russo L; Rosado E; Roglans N; Bosch J; García-Pagán JC
J Hepatol; 2012 May; 56(5):1033-1039. PubMed ID: 22245887
[TBL] [Abstract][Full Text] [Related]
26. Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats.
Cerini F; Vilaseca M; Lafoz E; García-Irigoyen O; García-Calderó H; Tripathi DM; Avila M; Reverter JC; Bosch J; Gracia-Sancho J; García-Pagán JC
J Hepatol; 2016 Apr; 64(4):834-42. PubMed ID: 26686269
[TBL] [Abstract][Full Text] [Related]
27. Sodium ferulate lowers portal pressure in rats with secondary biliary cirrhosis through the RhoA/Rho-kinase signaling pathway: a preliminary study.
Wei L; Yang J; Wang M; Xu SN; Liang HM; Zhou Q
Int J Mol Med; 2014 Nov; 34(5):1257-67. PubMed ID: 25174394
[TBL] [Abstract][Full Text] [Related]
28. Nebivolol treatment increases splanchnic blood flow and portal pressure in cirrhotic rats via modulation of nitric oxide signalling.
Reiberger T; Payer BA; Schwabl P; Hayden H; Horvatits T; Jäger B; Hummel T; Mitterhauser M; Trauner M; Fuhrmann V; Angermayr B; Peck-Radosavljevic M;
Liver Int; 2013 Apr; 33(4):561-8. PubMed ID: 23331709
[TBL] [Abstract][Full Text] [Related]
29. Sodium Ferulate Reduces Portal Pressure Through Inhibition of RhoA/Rho-Kinase and Activation of Endothelial Nitric Oxide Synthase in Cirrhotic Rats.
Liu J; Peng L; Yang J; Wang M; Xu S; Liu J; Han P; He J; Tian D; Zhou Q
Dig Dis Sci; 2015 Jul; 60(7):2019-29. PubMed ID: 25724163
[TBL] [Abstract][Full Text] [Related]
30. Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats.
Verbeke L; Farre R; Trebicka J; Komuta M; Roskams T; Klein S; Elst IV; Windmolders P; Vanuytsel T; Nevens F; Laleman W
Hepatology; 2014 Jun; 59(6):2286-98. PubMed ID: 24259407
[TBL] [Abstract][Full Text] [Related]
31. Three-day tetrahydrobiopterin therapy increases in vivo hepatic NOS activity and reduces portal pressure in CCl4 cirrhotic rats.
Matei V; Rodríguez-Vilarrupla A; Deulofeu R; García-Calderó H; Fernández M; Bosch J; Garcia-Pagán JC
J Hepatol; 2008 Aug; 49(2):192-7. PubMed ID: 18534709
[TBL] [Abstract][Full Text] [Related]
32. Evidence against a role for NADPH oxidase modulating hepatic vascular tone in cirrhosis.
Gracia-Sancho J; Laviña B; Rodríguez-Vilarrupla A; Brandes RP; Fernández M; Bosch J; García-Pagán JC
Gastroenterology; 2007 Sep; 133(3):959-66. PubMed ID: 17854599
[TBL] [Abstract][Full Text] [Related]
33. Cyclooxygenase-derived products modulate the increased intrahepatic resistance of cirrhotic rat livers.
Graupera M; García-Pagán JC; Abraldes JG; Peralta C; Bragulat M; Corominola H; Bosch J; Rodés J
Hepatology; 2003 Jan; 37(1):172-81. PubMed ID: 12500202
[TBL] [Abstract][Full Text] [Related]
34. Transplantation of endothelial progenitor cells ameliorates vascular dysfunction and portal hypertension in carbon tetrachloride-induced rat liver cirrhotic model.
Sakamoto M; Nakamura T; Torimura T; Iwamoto H; Masuda H; Koga H; Abe M; Hashimoto O; Ueno T; Sata M
J Gastroenterol Hepatol; 2013 Jan; 28(1):168-78. PubMed ID: 22849788
[TBL] [Abstract][Full Text] [Related]
35. Adenoviral dominant-negative soluble PDGFRβ improves hepatic collagen, systemic hemodynamics, and portal pressure in fibrotic rats.
Reichenbach V; Fernández-Varo G; Casals G; Oró D; Ros J; Melgar-Lesmes P; Weiskirchen R; Morales-Ruiz M; Jiménez W
J Hepatol; 2012 Nov; 57(5):967-73. PubMed ID: 22820479
[TBL] [Abstract][Full Text] [Related]
36. Terutroban, a thromboxane/prostaglandin endoperoxide receptor antagonist, increases survival in stroke-prone rats by preventing systemic inflammation and endothelial dysfunction: comparison with aspirin and rosuvastatin.
Gelosa P; Ballerio R; Banfi C; Nobili E; Gianella A; Pignieri A; Brioschi M; Guerrini U; Castiglioni L; Blanc-Guillemaud V; Lerond L; Tremoli E; Sironi L
J Pharmacol Exp Ther; 2010 Jul; 334(1):199-205. PubMed ID: 20332187
[TBL] [Abstract][Full Text] [Related]
37. Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats.
Trebicka J; Leifeld L; Hennenberg M; Biecker E; Eckhardt A; Fischer N; Pröbsting AS; Clemens C; Lammert F; Sauerbruch T; Heller J
Hepatology; 2008 Apr; 47(4):1264-76. PubMed ID: 18318439
[TBL] [Abstract][Full Text] [Related]
38. Role of gap junctions modulating hepatic vascular tone in cirrhosis.
Hernández-Guerra M; González-Méndez Y; de Ganzo ZA; Salido E; García-Pagán JC; Abrante B; Malagón AM; Bosch J; Quintero E
Liver Int; 2014 Jul; 34(6):859-68. PubMed ID: 24350605
[TBL] [Abstract][Full Text] [Related]
39. Defective endothelial nitric oxide synthase signaling is mediated by rho-kinase activation in rats with secondary biliary cirrhosis.
Anegawa G; Kawanaka H; Yoshida D; Konishi K; Yamaguchi S; Kinjo N; Taketomi A; Hashizume M; Shimokawa H; Maehara Y
Hepatology; 2008 Mar; 47(3):966-77. PubMed ID: 18167063
[TBL] [Abstract][Full Text] [Related]
40. The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells.
Vilaseca M; García-Calderó H; Lafoz E; García-Irigoyen O; Avila MA; Reverter JC; Bosch J; Hernández-Gea V; Gracia-Sancho J; García-Pagán JC
Hepatology; 2017 Jun; 65(6):2031-2044. PubMed ID: 28142199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
